As of 9:37am ET
| -0.00087 / -0.09%|
The 1 analysts offering 12-month price forecasts for Cancer Genetics Inc have a median target of 6.00, with a high estimate of 6.00 and a low estimate of 6.00. The median estimate represents a +545.76% increase from the last price of 0.93.
The current consensus among 3 polled investment analysts is to Hold stock in Cancer Genetics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.